“Dual trigger” was first introduced by Shapiro et al. (6) in co-treated patients with GnRH antagonist cycles for the purpose of Ovarian Hyperstimulation syndrome (OHSS) prevention. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.